Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ArmaGen Technologies Inc.

www.armagen.com

Latest From ArmaGen Technologies Inc.

Pipeline Watch: Peficitinib, Ubrogepant, Apalutamide Phase III Read-Outs

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Shire's Wellhoefer On Genetic Disease R&D And Expanding Access To Medicines

Scrip spoke with Shire's Head of Genetic Diseases, Medical Affairs, Hartmann Wellhoefer about upcoming milestones in the company's R&D pipeline and improving access to medicines for rare diseases after the Baxalta merger.

Commercial Business Strategies

WORLD Symposium Notebook: New Data In Lysosomal Diseases And A Push For Earlier Testing

The WORLD Symposium Feb. 13 to 16 in San Diego offered everything from basic research through late-stage clinical data in lysosomal diseases, including ArmaGen's blood-brain barrier-crossing treatment for Hurler syndrome and updates from ongoing development programs from rare disease specialists, such as Genzyme, Amicus and Protalix.

Commercial Clinical Trials

Pipeline Watch: Top-Line Tenapanor, Doravirine And Tofacitinib Results

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Neurogene Technologies Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ArmaGen Technologies Inc.
  • Senior Management
  • James Callaway, PhD, CEO
    William M Pardridge, MD, CSO
  • Contact Info
  • ArmaGen Technologies Inc.
    Phone: (818) 252-8200
    26679 Agoura Rd.
    Ste. 100
    Calabasas, CA 91302
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register